Hovione PharmaScience LTD. (Hovione Macau) was incorporated in Macau in 1984. The plant construction started immediately afterwards and production start-up took place in 1986.

In 1987 the Hovione Macau plant was inspected and approved by the FDA, allowing the export of Hovione Macau products to the United State pharmaceutical market. Since then the Hovione Macau plant has been regularly inspected by the FDA, last time being in November 2004. The facility is still the only plant in Macau, and one of the first ones in China, to be approved by the United States health authority.

In 2001, a new automated production building was commissioned which doubled the plant’s manufacturing capacity.

The facilities are certified in accordance with the ISO 9001 (Quality System) and the ISO 14001 (Environmental Management System).

Hovione Macau produces both generic and custom synthesis products. The United State is the main market for its products, followed by Europe, Australia, and New Zealand. Customers include leading generic companies, pharmaceutical multinationals and NASDAQ quoted biotech companies.

Hovione Macau employ around 120 persons with the vast majority involved in tasks requiring high technical expertise – quality assurance, quality control, process optimization. Production operators account for less than 30% of the total staff number. The majority of staff and managers are Macau born.